CO2021007402A2 - Constructos de suministro para transcitosis y métodos relacionados - Google Patents

Constructos de suministro para transcitosis y métodos relacionados

Info

Publication number
CO2021007402A2
CO2021007402A2 CONC2021/0007402A CO2021007402A CO2021007402A2 CO 2021007402 A2 CO2021007402 A2 CO 2021007402A2 CO 2021007402 A CO2021007402 A CO 2021007402A CO 2021007402 A2 CO2021007402 A2 CO 2021007402A2
Authority
CO
Colombia
Prior art keywords
transcytosis
related methods
methods
constructs
supply
Prior art date
Application number
CONC2021/0007402A
Other languages
English (en)
Spanish (es)
Inventor
Randall J Mrsny
Charles Olson
Amir Porat
Elbert Seto
Tahir Mahmood
Weijun Feng
Sally Postlethwaite
Original Assignee
Applied Molecular Transport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/021474 external-priority patent/WO2019173787A1/en
Priority claimed from PCT/US2019/050708 external-priority patent/WO2020096695A1/en
Application filed by Applied Molecular Transport Inc filed Critical Applied Molecular Transport Inc
Publication of CO2021007402A2 publication Critical patent/CO2021007402A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CONC2021/0007402A 2018-11-07 2021-06-07 Constructos de suministro para transcitosis y métodos relacionados CO2021007402A2 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862756889P 2018-11-07 2018-11-07
PCT/US2019/021474 WO2019173787A1 (en) 2018-03-08 2019-03-08 Toxin-derived delivery constructs for oral delivery
US201962888133P 2019-08-16 2019-08-16
US201962888238P 2019-08-16 2019-08-16
PCT/US2019/050708 WO2020096695A1 (en) 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload
PCT/US2019/060356 WO2020097394A1 (en) 2018-11-07 2019-11-07 Delivery constructs for transcytosis and related methods

Publications (1)

Publication Number Publication Date
CO2021007402A2 true CO2021007402A2 (es) 2021-09-30

Family

ID=70612266

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0007402A CO2021007402A2 (es) 2018-11-07 2021-06-07 Constructos de suministro para transcitosis y métodos relacionados

Country Status (21)

Country Link
US (3) US11027020B2 (https=)
EP (2) EP4083058A3 (https=)
JP (2) JP7516369B2 (https=)
KR (1) KR20210110294A (https=)
CN (1) CN113423722A (https=)
AU (1) AU2019377117B2 (https=)
BR (1) BR112021009003A2 (https=)
CA (1) CA3119060A1 (https=)
CL (1) CL2021001209A1 (https=)
CO (1) CO2021007402A2 (https=)
CY (1) CY1125216T1 (https=)
DK (1) DK3650037T3 (https=)
EA (1) EA202191280A1 (https=)
ES (1) ES2911075T3 (https=)
IL (1) IL282987B2 (https=)
MX (1) MX2021005346A (https=)
PL (1) PL3650037T3 (https=)
PT (1) PT3650037T (https=)
SG (1) SG11202104721RA (https=)
TW (1) TW202031678A (https=)
WO (1) WO2020097394A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN121513216A (zh) 2018-03-08 2026-02-13 应用分子转运公司 用于经口递送的毒素衍生的递送构建体
WO2020096695A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
EP4083058A3 (en) 2018-11-07 2023-01-11 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
KR20230044394A (ko) * 2020-06-09 2023-04-04 아이코사백스, 인크. 바이러스 유사 입자를 제조하는 방법
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
ATE412009T1 (de) * 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
DK1379273T3 (da) 2000-11-27 2009-11-09 Powderject Vaccines Inc Nukleinsyreadjuvanser
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
EP1644415B1 (en) * 2003-06-23 2010-12-01 Genetics Institute, LLC Antibodies against interleukin-22 and uses therefor
EP1522585A1 (en) 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines
US20090285771A1 (en) 2004-10-04 2009-11-19 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
WO2006135428A2 (en) 2004-10-04 2006-12-21 Trinity Biosystems, Inc. Methods and compositions for inducing an immune response against multiple antigens
WO2007067597A2 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
US20100143481A1 (en) 2006-11-08 2010-06-10 Dinesh Shenoy Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
US8524241B2 (en) 2007-07-20 2013-09-03 The General Hospital Corporation Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009149281A1 (en) 2008-06-04 2009-12-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins and uses thereof
NO2344540T3 (https=) 2008-10-02 2018-04-28
EP3366692A1 (en) * 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
JP2012533587A (ja) 2009-07-22 2012-12-27 セニックス バイオサイエンス ゲーエムベーハー 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
RU2593715C2 (ru) * 2010-09-15 2016-08-10 Рэндэлл Дж. МРСНИ Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина
US20140065172A1 (en) 2011-01-26 2014-03-06 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
PL2726091T3 (pl) 2011-06-29 2020-08-10 Rani Therapeutics, Llc Preparaty lecznicze dostarczane do kanału przewodu jelitowego za pomocą połykalnego urządzenia dostarczającego lek
WO2014145016A2 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
ES2739129T5 (es) 2013-11-07 2024-04-02 Memorial Sloan Kettering Cancer Center IL-22 para uso en el tratamiento de la enfermedad gastrointestinal del injerto contra el huesped
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
MX2016008979A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
CN106470707A (zh) 2014-05-07 2017-03-01 应用分子运输有限责任公司 用于口服递送生物活性货物的cholix毒素衍生的融合分子
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20170362291A1 (en) * 2014-12-23 2017-12-21 Armo Biosciences, Inc. Methods of Improving Yield in Recombinant Protein Production
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
JP2020513280A (ja) 2016-12-14 2020-05-14 プロジェニティ， インコーポレイテッド 消化管疾病の免疫抑制剤による治療
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2019173787A1 (en) * 2018-03-08 2019-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
EP4083058A3 (en) 2018-11-07 2023-01-11 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
US20200140511A1 (en) 2018-11-07 2020-05-07 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
WO2020096695A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload

Also Published As

Publication number Publication date
ES2911075T3 (es) 2022-05-17
JP7516369B2 (ja) 2024-07-16
MX2021005346A (es) 2021-10-13
IL282987B (en) 2022-10-01
CL2021001209A1 (es) 2021-11-19
AU2019377117A1 (en) 2021-06-10
AU2019377117B2 (en) 2025-05-29
WO2020097394A1 (en) 2020-05-14
EP4083058A2 (en) 2022-11-02
EA202191280A1 (ru) 2021-12-27
EP4083058A3 (en) 2023-01-11
US11027020B2 (en) 2021-06-08
EP3650037A1 (en) 2020-05-13
IL282987B2 (en) 2023-02-01
TW202031678A (zh) 2020-09-01
JP2022506990A (ja) 2022-01-17
US20240238429A1 (en) 2024-07-18
CN113423722A (zh) 2021-09-21
JP2024127939A (ja) 2024-09-20
CA3119060A1 (en) 2020-05-14
US20210338828A1 (en) 2021-11-04
KR20210110294A (ko) 2021-09-07
PT3650037T (pt) 2022-06-27
BR112021009003A2 (pt) 2021-08-17
DK3650037T3 (da) 2022-05-02
SG11202104721RA (en) 2021-06-29
EP3650037B1 (en) 2022-03-02
CY1125216T1 (el) 2024-12-13
IL282987A (en) 2021-06-30
US20200306383A1 (en) 2020-10-01
PL3650037T3 (pl) 2022-06-06

Similar Documents

Publication Publication Date Title
CO2021007402A2 (es) Constructos de suministro para transcitosis y métodos relacionados
CL2021002094A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153)
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
MX389700B (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
MX2014003677A (es) Proteinas de fusion para el tratamiento de trastornos metabolicos.
CO7111276A2 (es) Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met
CO2023005057A2 (es) Compuestos y composiciones como moduladores de señalización tlr
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
DOP2019000112A (es) PIRIDO[3,4-b]INDOLES SUSTITUIDOS PARA TRATAMIENTO DE LOS TRASTORNOS DE LOS CARTÍLAGOS
CO2021013171A2 (es) Compuestos y composiciones como moduladores de la señalización de tlr
MY207469A (en) Therapeutic compounds
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2018009189A (es) Compuestos de anillo de siete miembros de pirimidina.
CL2018002430A1 (es) Proteínas de fusión de enzimas lisosomales terapéuticas dirigidas, formulaciones asociadas y usos de las mismas
MX2020008852A (es) Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparacion y uso de las mismas.
CO2024007013A2 (es) Isoxazolidinas como inhibidores de ripk1 y uso de estas
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
AR117017A1 (es) Constructos de entrega para transcitosis y métodos relacionados
CL2023000013A1 (es) Compuestos y composiciones como moduladores de la señalización tlr
CO2025009498A2 (es) Formulaciones de bezuclastinib